The 12 closest competitors and alternatives to Ultragenyx among biotech companies — ranked by similarity to what Ultragenyx actually does, not by market-cap band.
Subscribe to see Ultragenyx’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is a biotech company headquartered in Japan. Xcout tracks 16 named people at Ultragenyx, including Howard Horn (Chief Financial Officer and Executive Vice President, Corporate Strategy). Xcout recorded 66 job postings from Ultragenyx in the last 90 days, naming tools such as SAP, Cisco, Meraki.
10 more named people on record for Ultragenyx, with roles, board committees and tenure — see the full roster →
Xcout recorded 66 job postings from Ultragenyx in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Ultragenyx's hiring signals →
Ranked by semantic similarity — how close each company is to Ultragenyx by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Travere Therapeutics is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing, and delivering life-changing therapies for people living with rare diseases.
Biotechnology
Applied Therapeutics, Inc. is a biopharmaceutical company headquartered in New York City, focused on developing novel product candidates targeted at disease targets involving enzyme and metabolic pathways.
Similar biotech company
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Biotechnology
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders.
Similar biotech company
Orchard Therapeutics plc is a biopharmaceutical company with operations including a U.S. headquarters located in Boston, Massachusetts.
Similar biotech company
Amicus Therapeutics, Inc. is an American biopharmaceutical company focused on discovering and delivering advanced therapies for rare diseases. The company is publicly traded on Nasdaq and maintains its global corporate headquarters in Princeton, New Jersey.
Biotechnology
AM-Pharma is a biopharmaceutical company based in Utrecht, the Netherlands, focused on developing proprietary recombinant human alkaline phosphatase therapeutics like ilofotase alfa for severe medical conditions.
Biotechnology
Homology Medicines, Inc. is a clinical-stage genetic medicines company historically focused on transforming the lives of patients with rare diseases through genetic treatments.
Biotechnology
Amicus Therapeutics, a subsidiary of BioMarin Pharmaceutical Inc., is a biotechnology company that researches and delivers medicines for individuals living with genetically defined rare diseases. The company provides patient advocacy and support services alongside its clinical development pipeline.
Biotechnology
Arbor Biotechnologies, Inc. is a next-generation gene editing company focused on discovering and developing precise genetic medicines for rare and complex diseases.
Biotechnology
Dynacure is a biotechnology company developing antisense oligonucleotide therapies for rare neuromuscular diseases. Its lead program, DYN101, targets DNM2-associated centronuclear myopathy for patients with this serious inherited muscle disorder.
Similar biotech company
Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Ultragenyxand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →